Articoli con mandati relativi all'accesso pubblico - Hans PrenenUlteriori informazioni
Non disponibili pubblicamente: 7
Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor–associated PDGFRAD842V mutation
B Dewaele, B Wasag, J Cools, R Sciot, H Prenen, P Vandenberghe, ...
Clinical Cancer Research 14 (18), 5749-5758, 2008
Mandati: Research Foundation (Flanders)
Targeting hedgehog signaling in pancreatic ductal adenocarcinoma
D Quatannens, Y Verhoeven, P Van Dam, F Lardon, H Prenen, G Roeyen, ...
Pharmacology & Therapeutics 236, 108107, 2022
Mandati: Research Foundation (Flanders)
Administration of imatinib mesylate in rats impairs the neonatal development of intramuscular interstitial cells in bladder and results in altered contractile properties
T Gevaert, G Hutchings, W Everaerts, H Prenen, T Roskams, B Nilius, ...
Neurourology and urodynamics 33 (4), 461-468, 2014
Mandati: Research Foundation (Flanders)
Impact of molecular markers on treatment selection in advanced colorectal cancer
H Prenen, S Tejpar, E Van Cutsem
European Journal of Cancer 45, 70-78, 2009
Mandati: Research Foundation (Flanders)
Successful application of endoscopic ultrasound-guided fine needle biopsy to establish pancreatic patient-derived tumor xenografts: a pilot study
E Hermans, SW Van der Merwe, J Depreeuw, J Dekervel, E Radaelli, ...
Endoscopy 48 (11), 1016-1022, 2016
Mandati: Research Foundation (Flanders)
Ramucirumab: The long and winding road toward being an option for mCRC treatment
C Debeuckelaere, S Murgioni, S Lonardi, N Girardi, G Alberti, C Fano, ...
Expert opinion on biological therapy 19 (5), 399-409, 2019
Mandati: Governo Italiano
A systematic review of patient-derived tumor organoids generation from malignant effusions
S Seghers, M Le Compte, JMH Hendriks, P Van Schil, A Janssens, ...
Critical Reviews in Oncology/Hematology 195, 104285, 2024
Mandati: Research Foundation (Flanders)
Disponibili pubblicamente: 52
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
A Drilon, S Siena, R Dziadziuszko, F Barlesi, MG Krebs, AT Shaw, ...
The Lancet Oncology 21 (2), 261-270, 2020
Mandati: US National Institutes of Health, National Institute for Health Research, UK
MET is required for the recruitment of anti-tumoural neutrophils
V Finisguerra, G Di Conza, M Di Matteo, J Serneels, S Costa, ...
Nature 522 (7556), 349-353, 2015
Mandati: Research Foundation (Flanders), UK Medical Research Council, National …
Macrophage metabolism controls tumor blood vessel morphogenesis and metastasis
M Wenes, M Shang, M Di Matteo, J Goveia, R Martín-Pérez, J Serneels, ...
Cell metabolism 24 (5), 701-715, 2016
Mandati: Research Foundation (Flanders), European Commission
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer
H Prenen, J De Schutter, B Jacobs, W De Roock, B Biesmans, B Claes, ...
Clinical cancer research 15 (9), 3184-3188, 2009
Mandati: Research Foundation (Flanders)
Podoplanin-expressing macrophages promote lymphangiogenesis and lymphoinvasion in breast cancer
P Bieniasz-Krzywiec, R Martín-Pérez, M Ehling, M García-Caballero, ...
Cell metabolism 30 (5), 917-936. e10, 2019
Mandati: Research Foundation (Flanders), Worldwide Cancer Research, UK, European …
Common variants at the MHC locus and at chromosome 16q24. 1 predispose to Barrett's esophagus
Esophageal Adenocarcinoma Genetics Consortium, ...
Nature genetics 44 (10), 1131-1136, 2012
Mandati: US National Institutes of Health, National Health and Medical Research …
Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis
P Gharahkhani, RC Fitzgerald, TL Vaughan, C Palles, I Gockel, ...
The lancet oncology 17 (10), 1363-1373, 2016
Mandati: US National Institutes of Health, Australian Research Council, National …
BOB CAT: a large-scale review and Delphi consensus for management of Barrett’s esophagus with no dysplasia, indefinite for, or low-grade dysplasia
C Bennett, P Moayyedi, DA Corley, J DeCaestecker, Y Falck-Ytter, G Falk, ...
Official journal of the American College of Gastroenterology| ACG 110 (5 …, 2015
Mandati: US National Institutes of Health, National Institute for Health Research, UK
Cancer risk in immune-mediated inflammatory diseases (IMID)
R Beyaert, L Beaugerie, G Van Assche, L Brochez, JC Renauld, M Viguier, ...
Molecular cancer 12, 1-12, 2013
Mandati: Research Foundation (Flanders)
Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis
L De Smedt, J Lemahieu, S Palmans, O Govaere, T Tousseyn, ...
British journal of cancer 113 (3), 500-509, 2015
Mandati: National Fund for Scientific Research, Belgium, Research Foundation (Flanders)
Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer
E Van Cutsem, C Eng, E Nowara, A Świeboda-Sadlej, NC Tebbutt, ...
Clinical Cancer Research 20 (16), 4240-4250, 2014
Mandati: US National Institutes of Health
Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett’s esophagus
C Palles, L Chegwidden, X Li, JM Findlay, G Farnham, FC Giner, ...
Gastroenterology 148 (2), 367-378, 2015
Mandati: US National Institutes of Health, Cancer Research UK, UK Medical Research …
The mTOR and PP2A pathways regulate PHD2 phosphorylation to fine-tune HIF1α levels and colorectal cancer cell survival under hypoxia
G Di Conza, ST Cafarello, S Loroch, D Mennerich, S Deschoemaeker, ...
Cell reports 18 (7), 1699-1712, 2017
Mandati: Research Foundation (Flanders), German Research Foundation, European …
Le informazioni sulla pubblicazione e sul finanziamento vengono stabilite automaticamente da un software